Current Medical Research and Opinion 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Sex differences in clinical features, utilization of oral anticoagulant agents, and one-year outcome in Middle Eastern patients with atrial fibrillation
CONCLUSION: Females with AF are more symptomatic, yet they are treated less with rhythm control. Despite higher risk, females have similar risk-adjusted all-cause cardiovascular death and stroke rates compared to males. Future studies should explore how treatments and interventions can influence quality of life and cardiovascular outcomes in females with AF.PMID:38507072 | DOI:10.1080/03007995.2024.2332440 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - March 20, 2024 Category: Research Authors: Nasr Alrabadi Mohammed Al-Nusair Razan Haddad Basheer S Alghizzawi Nashmi Al-Nusair Saleh Alhaj Mohammad Saif M Shteiwi Maryam K El-Zubi Zaid Marie Ayham Alnsour Mohamad Jarrah Karem H Alzoubi Ayman Hammoudeh Source Type: research
Clinical validation of a fast-acting acetaminophen: a randomized, active and placebo controlled dental pain study
Conclusions: This study supports previous studies, demonstrating faster onset of analgesia with FA-acetaminophen 1000 mg compared to OTC ES-acetaminophen 1000 mg and OTC LG-ibuprofen 400 mg.ClinicalTrials.gov Identifier: NCT03224403 https://clinicaltrials.gov/ct2/show/NCT03224403.PMID:38505928 | DOI:10.1080/03007995.2024.2331159 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - March 20, 2024 Category: Research Authors: Andrew Myers Todd Bertoch Paul Zhang Stephen A Cooper Source Type: research
Preferences of healthcare providers in Switzerland for attributes of pediatric hexavalent vaccines: a discrete-choice experiment
CONCLUSION: Hib seroprotection at 11-12 months was the most important hexavalent vaccine attribute to HCPs in this study.PMID:38501272 | DOI:10.1080/03007995.2024.2325550 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - March 19, 2024 Category: Research Authors: Salome Samant Susanne Oberle Tomas Marcek Christine Poulos Phani Chintakayala Edith Langevin Tanaz Petigara Marco Boeri Source Type: research
Addressing hepatitis delta in primary care practices in the US: a narrative review
CONCLUSIONS: PCPs can be a valuable point of care for patients to access HDV/HBV screening, HBV immunization, and education, and can comanage patients with HBV and/or HDV infection.PMID:38487951 | DOI:10.1080/03007995.2024.2318004 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - March 15, 2024 Category: Research Authors: Tatyana Kushner Richard R Andrews Source Type: research
Evaluation of effect of brief-intensive cognitive behavior therapy on symptoms severity in relation with catastrophic cognition in patients with panic disorder: a randomized controlled trial
CONCLUSIONS: The study showed that brief-intensive CBT is an effective technique for reducing the severity of symptoms among PD patients. But, it was not effective to improve the cognitive level in PD patients at one month.PMID:38465410 | DOI:10.1080/03007995.2024.2328651 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - March 11, 2024 Category: Research Authors: Rasoul Sabri Piro Perjan Hashim Taha Source Type: research
Treatment patterns and outcomes among adults with immune thrombocytopenia receiving pharmaceutical second-line therapies: a retrospective cohort study using administrative claims data
Conclusion: Patients with ITP receiving rituximab were more likely to need other ITP therapies but did not experience higher risk of bleeding compared to those receiving eltrombopag or romiplostim. Benefits, risks, cost-effectiveness, and patient preference should all be considered in optimizing second-line therapy for ITP.PMID:38465414 | DOI:10.1080/03007995.2024.2328653 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - March 11, 2024 Category: Research Authors: Yi Liang Karen Rascati Jamie C Barner Kenneth A Lawson Radhika Nair Source Type: research
Evaluation of effect of brief-intensive cognitive behavior therapy on symptoms severity in relation with catastrophic cognition in patients with panic disorder: a randomized controlled trial
Conclusions: The study showed that brief-intensive CBT is an effective technique for reducing the severity of symptoms among PD patients. But, it was not effective to improve the cognitive level in PD patients at one month.Trial Registration: The study received ethical approval from the Duhok Directorate General of Health registered with the reference number 1808202 l-8-5 on August 18, 2021.PMID:38465410 | DOI:10.1080/03007995.2024.2328651 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - March 11, 2024 Category: Research Authors: Rasoul Sabri Piro Perjan Hashim Taha Source Type: research
Treatment patterns and outcomes among adults with immune thrombocytopenia receiving pharmaceutical second-line therapies: a retrospective cohort study using administrative claims data
Conclusion: Patients with ITP receiving rituximab were more likely to need other ITP therapies but did not experience higher risk of bleeding compared to those receiving eltrombopag or romiplostim. Benefits, risks, cost-effectiveness, and patient preference should all be considered in optimizing second-line therapy for ITP.PMID:38465414 | DOI:10.1080/03007995.2024.2328653 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - March 11, 2024 Category: Research Authors: Yi Liang Karen Rascati Jamie C Barner Kenneth A Lawson Radhika Nair Source Type: research
Evaluation of effect of brief-intensive cognitive behavior therapy on symptoms severity in relation with catastrophic cognition in patients with panic disorder: a randomized controlled trial
Conclusions: The study showed that brief-intensive CBT is an effective technique for reducing the severity of symptoms among PD patients. But, it was not effective to improve the cognitive level in PD patients at one month.Trial Registration: The study received ethical approval from the Duhok Directorate General of Health registered with the reference number 1808202 l-8-5 on August 18, 2021.PMID:38465410 | DOI:10.1080/03007995.2024.2328651 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - March 11, 2024 Category: Research Authors: Rasoul Sabri Piro Perjan Hashim Taha Source Type: research
Treatment patterns and outcomes among adults with immune thrombocytopenia receiving pharmaceutical second-line therapies: a retrospective cohort study using administrative claims data
Conclusion: Patients with ITP receiving rituximab were more likely to need other ITP therapies but did not experience higher risk of bleeding compared to those receiving eltrombopag or romiplostim. Benefits, risks, cost-effectiveness, and patient preference should all be considered in optimizing second-line therapy for ITP.PMID:38465414 | DOI:10.1080/03007995.2024.2328653 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - March 11, 2024 Category: Research Authors: Yi Liang Karen Rascati Jamie C Barner Kenneth A Lawson Radhika Nair Source Type: research
Evaluation of effect of brief-intensive cognitive behavior therapy on symptoms severity in relation with catastrophic cognition in patients with panic disorder: a randomized controlled trial
Conclusions: The study showed that brief-intensive CBT is an effective technique for reducing the severity of symptoms among PD patients. But, it was not effective to improve the cognitive level in PD patients at one month.Trial Registration: The study received ethical approval from the Duhok Directorate General of Health registered with the reference number 1808202 l-8-5 on August 18, 2021.PMID:38465410 | DOI:10.1080/03007995.2024.2328651 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - March 11, 2024 Category: Research Authors: Rasoul Sabri Piro Perjan Hashim Taha Source Type: research
Treatment patterns and outcomes among adults with immune thrombocytopenia receiving pharmaceutical second-line therapies: a retrospective cohort study using administrative claims data
Conclusion: Patients with ITP receiving rituximab were more likely to need other ITP therapies but did not experience higher risk of bleeding compared to those receiving eltrombopag or romiplostim. Benefits, risks, cost-effectiveness, and patient preference should all be considered in optimizing second-line therapy for ITP.PMID:38465414 | DOI:10.1080/03007995.2024.2328653 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - March 11, 2024 Category: Research Authors: Yi Liang Karen Rascati Jamie C Barner Kenneth A Lawson Radhika Nair Source Type: research
